Replimune Group, Inc. (REPL)
4.67
+0.07
(+1.52%)
USD |
NASDAQ |
May 27, 15:41
Replimune Group Free Cash Flow : -283.27M for Dec. 31, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| REGENXBIO, Inc. | -236.40M |
| Catalyst Pharmaceuticals, Inc. | 208.13M |
| Spyre Therapeutics, Inc. | -185.87M |
| Bristol Myers Squibb Co. | 11.91B |
| ANI Pharmaceuticals, Inc. | 182.81M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -65.96M |
| Cash from Investing (Quarterly) | 75.12M |
| Cash from Financing (Quarterly) | 10.45M |
| Free Cash Flow Per Share (Quarterly) | -0.7169 |
| Free Cash Flow to Equity (Quarterly) | -66.11M |
| Free Cash Flow to Firm (Quarterly) | -64.13M |
| Free Cash Flow Yield | -68.79% |